Ancora Heart
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Ancora Heart sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Ancora Heart: 4 sponsored US clinical trials, 1 recruiting.
Ancora Heart sponsors 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 2 completed. The most-studied condition in this pipeline is Cardiomyopathy, Dilated, with 1 trials.
Upper-quartile sponsor footprint
Ancora Heart sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study
NCT04331769
Early Feasibility Evaluation of the AccuCinch® Ventricular Restoration System in Patients With Heart Failure and Reduced Ejection Fraction
NCT03533517
Early Feasibility Study of the AccuCinch® Ventricular Restoration System in Patients With Prior Mitral Valve Intervention (PMVI) and Recurrent Mitral Regurgitation
NCT03560167
The CorCinch - Functional Mitral Valve Regurgitation (FMR) Study
NCT02806570
Therapeutic Areas
What is open in the Ancora Heart pipeline
1 recruiting of 4 indexed (25% open); 2 completed (50%).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: Cardiomyopathy, Dilated (1 trial), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Ancora Heart: open-pipeline peers nationwide
Peers matched on 4 registered trials and 25% open enrollment, not the therapeutic-area sidebar.
Ancora Heart sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 25% open enrollment (± trial volume)
- AB Science · 25% recruiting · 8 trials
- Abbott Point of Care · 25% recruiting · 8 trials
- Accutar Biotechnology · 25% recruiting · 4 trials
- Adrienne G. Waks · 25% recruiting · 4 trials
Related
What to do with this Ancora Heart page
4 registered trials is a research-attention snapshot, not an endorsement of Ancora Heart or any single study.
- 1 of Ancora Heart's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Cardiomyopathy, Dilated is the condition Ancora Heart studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cardiomyopathy, Dilated trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Ancora Heart pipeline card: 4 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.